<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823613</url>
  </required_header>
  <id_info>
    <org_study_id>RZL-SDU-IMM-CVR</org_study_id>
    <nct_id>NCT02823613</nct_id>
  </id_info>
  <brief_title>The Influence of High and Low Salt on Exosomes in the Urine</brief_title>
  <official_title>The Influence of High and Low Salt on Exosomes in the Urine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Diabetes Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beckett Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that changes in the epithelial sodium channel (ENaC) in the kidney is
      reflected in urinary exosomes and that the amount of ENaC as well as the cleavage degree is
      upregulated in conditions with low salt.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:

      Exosomes will be isolated from spot urine by ultracentrifugation and tested using western
      blotting. In-house developed antibodies against different parts of the ENaC gamma subunit as
      well as commercial antibodies will be used. A marker for exosomes will validate the presence
      of exosomes in the urine.

      Power considerations:

      In this cross over salt-intervention study with quantification of ENaC the investigators
      refer to a published study regarding the sodium-chloride co-transporter (NCC) in the kidney,
      were rats where given aldosterone infusion or a low salt diet. In this study n=6 was
      sufficient to detect a 2-3 fold change in NCC in urinary exosomes. Furthermore 5 patients
      with primary aldosteronism had a significant increase in NCC in urinary exosomes (N. Lubbe et
      al, Hypertension 2012).

      On the basis of this the investigators choose to test 10 persons, but are not able to make a
      regular power calculation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in epithelial sodium channel (ENaC) appearance in urinary exosomes</measure>
    <time_frame>After 5 days on high or low salt diet</time_frame>
    <description>Semiquantitative western blotting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone</measure>
    <time_frame>Before study start and after 5 days on high or low salt diet</time_frame>
    <description>Concentration in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>Before study start and after 5 days on high or low salt diet</time_frame>
    <description>Concentration in plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy male test subjects 1-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High salt diet followed by low salt diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy male test subjects 6-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low salt diet followed by high salt diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High salt diet followed by low salt diet</intervention_name>
    <description>High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.</description>
    <arm_group_label>Healthy male test subjects 1-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low salt diet followed by high salt diet</intervention_name>
    <description>Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.</description>
    <arm_group_label>Healthy male test subjects 6-10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men aged 20-40

          -  Body Mass Index (BMI, weight/height^2) between 18 and 25.

        Exclusion Criteria:

          -  Increased blood pressure (hypertension) or in treatment for high blood pressure

          -  Diabetes

          -  Regular medical intake

          -  Smoking

          -  Expectation of lacking cooperation or lack of understanding of the experiment

          -  Clinical relevant organic or systemic disease including malign disease

          -  Decreased kidney function
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boye L Jensen, dr.med., phd</last_name>
    <role>Study Director</role>
    <affiliation>Cardiovascular and Renal Research, Institute of Moleculare Medicine, University of Southern Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern Denmark</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Zachar RM, Skjødt K, Marcussen N, Walter S, Toft A, Nielsen MR, Jensen BL, Svenningsen P. The epithelial sodium channel γ-subunit is processed proteolytically in human kidney. J Am Soc Nephrol. 2015 Jan;26(1):95-106. doi: 10.1681/ASN.2013111173. Epub 2014 Jul 24.</citation>
    <PMID>25060057</PMID>
  </reference>
  <reference>
    <citation>van der Lubbe N, Jansen PM, Salih M, Fenton RA, van den Meiracker AH, Danser AH, Zietse R, Hoorn EJ. The phosphorylated sodium chloride cotransporter in urinary exosomes is superior to prostasin as a marker for aldosteronism. Hypertension. 2012 Sep;60(3):741-8. doi: 10.1161/HYPERTENSIONAHA.112.198135. Epub 2012 Jul 30.</citation>
    <PMID>22851731</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Rikke Zachar Langkilde</investigator_full_name>
    <investigator_title>MD, phd student</investigator_title>
  </responsible_party>
  <keyword>ENaC</keyword>
  <keyword>Exosomes</keyword>
  <keyword>Urinary biomarker</keyword>
  <keyword>Salt regulation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

